Perigo (PRGO) Q1 2025: Gross Margin Expands 440bps as Tariff Mitigation and Brand Growth Offset Macro Drag

May 7, 2025 | By EarningsIQ Research

Perigo’s Q1 marked a decisive inflection in margin structure, with a 440 basis point gross margin expansion fueled by infant formula recovery and operational streamlining, even as macro headwinds and tariffs prompted a wider sales outlook. Management’s disciplined cost actions, supply chain localization, and brand investments signal a business model built for resilience and incremental upside as consumer trade-down accelerates. With international now contributing over 40% of sales and outpacing Americas in profit growth, Perigo’s portfolio is shifting toward higher-margin, diversified growth levers.

Summary

• Margin Structure Reset: Gross margin expansion and cost savings from Project Energize underpin profit resilience.
• Infant Formula and OTC Brand Momentum: Recovery in infant formula and nearly 6% OTC brand growth offset legacy headwinds.
• Strategic Levers for Volatility: Tariff mitigation, supply chain localization, and value-tier share gains position Perigo for macro uncertainty.

Performance Analysis

Perigo’s Q1 performance pivoted on a robust margin reset, with gross margin expanding 440 basis points to 41% and operating margin up 550 basis points, both driven primarily by the recovery in infant formula and benefits from Project Energize, a cost reduction initiative delivering $159 million in annualized savings. Organic net sales declined 0.4%, but when excluding legacy distribution losses and prior-year retailer stocking, organic net sales grew 1.8%, reflecting underlying demand strength in branded OTC and infant formula.

International operations, now over 40% of total sales, delivered mid-single-digit sales growth and double-digit operating income gains, nearly matching the Americas in profitability and narrowing the segment gap. OTC brands posted 5.9% organic growth, driven by strong sales of LL1, Nasernet, Equitin, and Compete, while infant formula net sales surged 19% year-over-year as shelf presence and SKUs were restored. Cash flow was seasonally negative due to inventory rebuild and litigation, but management reaffirmed leverage targets and capital discipline.

• Cost and Margin Leverage: Supply chain reinvention and Project Energize drove $28 million in incremental savings, funding brand investments and margin expansion.
• Infant Formula Recovery: High-quality production and shelf resets restored share, with 60 new SKUs set to accelerate growth in H2.
• International Profit Surge: International segment operating income grew over 10%, with revenue now 4.5 times the size of infant formula.

While topline growth remains muted by legacy headwinds and macro drag, the operational and margin reset provides a foundation for earnings durability and optionality as consumer trade-down and contract manufacturing opportunities rise.

Executive Commentary

Strategic Positioning

1. Supply Chain Localization and Tariff Mitigation

Perigo’s operational flexibility is a core differentiator as tariffs and supply chain volatility intensify. With 85% of U.S. OTC finished goods produced domestically and most materials sourced locally, the company’s exposure to tariffs is limited primarily to oral care and select OTC inputs. Management is offsetting a projected $145–$155 million annual tariff impact through strategic price actions, insourcing, and alternative sourcing—actions expected to fully neutralize P&L headwinds through 2027.

2. Store Brand and Value-Tier Share Gains

Perigo’s dual model—store brands and proprietary OTC brands—enables it to capture share as consumers trade down amid weak confidence. Store brand OTC volume gained 50 basis points in recent weeks, and new business awards are on track to more than offset prior distribution losses by Q2. The company’s 100% price point coverage and 100-plus molecules portfolio provide a resilient demand base in volatile markets.

3. Brand-Led Growth and Innovation Pipeline

OTC brand growth was nearly 6% organically, with key brands outperforming and benefiting from cash flow generated by the store brand engine. Management has enhanced its stage-gate new product process and is preparing to launch a high-growth brand in 2026. Reinvestment in brands and shelf resets—especially in infant formula—are expected to drive mix and margin tailwinds in the second half.

4. International Acceleration and Portfolio Diversification

International is now a central profit driver, delivering mid-single-digit sales growth and double-digit operating income expansion. The segment is nearly as profitable as the Americas and is four-and-a-half times the size of the infant formula business, providing diversification and a hedge against U.S.-centric risks.

5. Disciplined Capital Allocation and Cash Flow Management

Capital investments in nutrition optimization have been paused pending macro clarity, while working capital improvements and cost actions are prioritized to protect leverage and dividend capacity. Cash flow is expected to improve sharply in H2 as inventory normalizes and tariff mitigation actions take hold.

Key Considerations

Perigo’s Q1 results reflect a business in strategic transition, balancing macro caution with operational execution and emerging growth levers. Investors should monitor:

Key Considerations:

• Margin Expansion Durability: Sustainability of Q1’s 440bps gross margin gain as brand reinvestment and mix shift accelerate.
• Tariff Pass-Through Effectiveness: Ability to execute price increases and insourcing in oral care and OTC without volume attrition.
• Infant Formula Share Recovery: Impact of 60 new SKUs and shelf resets on H2 growth, amid aggressive national brand promotions.
• International Segment Leverage: Continued outperformance and profit contribution as a buffer to U.S. macro and competitive risks.
• Cash Flow Timing: Pace of inventory normalization and working capital release as litigation and restructuring costs subside.

Risks

Macro uncertainties—consumer confidence, inflation, and tariffs—remain a material overhang, with Perigo widening its net sales outlook to reflect volatility. Aggressive national brand promotions in infant formula and shifting category consumption patterns could pressure share and price gaps. Tariff escalation or regulatory shifts in pharma and nutrition supply chains present additional downside risk, though management’s playbook for mitigation is well developed.

Forward Outlook

For Q2 2025, Perigo expects:

• New business awards in store brand OTC to offset prior distribution losses, driving sequential sales improvement.
• Infant formula sales to remain strong, with a material ramp in H2 as new SKUs and shelf resets hit the market.

For full-year 2025, management maintained guidance:

• Adjusted EPS of $2.90–$3.10, reflecting double-digit growth.
• Net leverage target of 3.5x by year-end.

Management highlighted several factors that will shape results:

• Execution of price actions and supply chain localization to offset tariffs.
• Acceleration of value-tier and store brand share gains as consumers trade down.

Takeaways

Perigo’s Q1 marks a structural margin reset and a pivot toward diversified, higher-margin growth, with supply chain localization and disciplined capital allocation providing insulation from macro shocks.

• Margin Reset and Cost Control: Project Energize and supply chain initiatives are driving sustainable margin expansion and funding brand investments.
• Portfolio Shift to Higher-Margin Brands: OTC brands and international now anchor profit growth, reducing reliance on lower-margin U.S. store brands.
• Watch for H2 Revenue Inflection: Ramp of new infant formula SKUs, contract manufacturing wins, and further tariff mitigation will be critical for sustaining EPS guidance and leverage targets.

Conclusion

Perigo’s Q1 delivered a decisive margin and profit inflection, with operational discipline and portfolio diversification offsetting macro and tariff headwinds. The business is positioned for resilient earnings and incremental upside as value-tier share gains and international growth accelerate into the second half.

Industry Read-Through

Perigo’s results reinforce the defensive strength of value-tier and store brand models as consumer confidence wanes. Margin reset via domestic supply chain localization and disciplined cost actions are likely to become standard playbooks for peers facing tariff and macro volatility. Aggressive national brand promotions in infant formula signal a competitive response that could pressure price gaps across the category, while contract manufacturing demand is set to rise as brands seek U.S.-based supply. International diversification is increasingly vital for consumer health companies to buffer U.S.-centric shocks and capture growth in less saturated markets.

PRGO Healthcare Consumer Health Brand Diversification Tariffs Margin Expansion Store Brands Supply Chain